Skip to content

Study · Animal study (in vivo) · sprague-dawley rats · 2020

4 results

MicroRNA levels in bone and blood change during bisphosphonate and teriparatide therapy in an animal model of postmenopausal osteoporosis.

Kocijan R, Weigl M, Skalicky S, Geiger E, Ferguson J, Leinfellner G, Heimel P, Pietschmann P, Grillari J, Redl H, Hackl M

Bone1 Nov 2019Cited by 45 (Europe PMC)

PMID31683019 (opens in a new tab)DOI10.1016/j.bone.2019.115104 (opens in a new tab)PepBankPUB-31683019
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized rats, teriparatide fully rescued trabecular bone loss.

    In plain wordsIn rats with ovaries removed, teriparatide fully reversed the loss of spongy bone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseTrabecular bone loss
    Study

    Sprague-Dawley ratsn: not reported in source

    Ovariectomized rats
    Comparator
    Untreated ovariectomized rats
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 12 weeksAs given in this study (Sprague-Dawley rats).

    Source sentences

    Summary
    Ovariectomy resulted in loss of trabecular bone, which was fully rescued using osteo-anabolic treatment, and partially rescued using anti-resorptive treatment.
    2 context sentences
    Summary · context
    Eight weeks after surgery, OVX animals were further randomized to anti-resorptive treatment with zoledronate (n=11), osteo-anabolic treatment with teriparatide (n=11), or vehicle treatment (n=10).
    Summary · context
    After 12 weeks of treatment, bone and serum samples were used for microRNA analysis using next-generation sequencing (NGS), mRNA levels using RT-qPCR, and bone microarchitecture analysis using nanoCT.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In ovariectomized rats, teriparatide significantly regulated 46 detected miRNAs in an analysis of bone tissue and serum.

    In plain wordsIn rats with ovaries removed, teriparatide changed 46 miRNAs in an analysis of bone tissue and serum.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    MixedmiRNA regulation in bone and serum
    Study

    Sprague-Dawley ratsn: not reported in source

    Ovariectomized rats
    Comparator
    Untreated ovariectomized rats
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 12 weeksAs given in this study (Sprague-Dawley rats).

    Measurements

    Regulated miRNAs
    46 miRNAs
    teriparatide treatment

    Source sentences

    Summary
    NGS revealed that both, anti-resorptive and anabolic treatment had a significant impact on miRNA levels in bone tissue and serum: out of 426 detected miRNAs, 46 miRNAs were regulated by teriparatide treatment an d 10 by zoledronate treatment (p-adj.<0.1).
    2 context sentences
    Summary · context
    Eight weeks after surgery, OVX animals were further randomized to anti-resorptive treatment with zoledronate (n=11), osteo-anabolic treatment with teriparatide (n=11), or vehicle treatment (n=10).
    Summary · context
    After 12 weeks of treatment, bone and serum samples were used for microRNA analysis using next-generation sequencing (NGS), mRNA levels using RT-qPCR, and bone microarchitecture analysis using nanoCT.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In ovariectomized rats, teriparatide reversed miRNA changes in tissue and serum, including miR-203a-3p upregulation in untreated animals.

    In plain wordsIn rats with ovaries removed, teriparatide reversed miRNA changes, including the rise in miR-203a-3p seen without treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreasemiR-203a-3p upregulation
    Study

    Sprague-Dawley ratsn: not reported in source

    Ovariectomized rats
    Comparator
    Untreated ovariectomized rats
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 12 weeksAs given in this study (Sprague-Dawley rats).

    Source sentences

    Summary
    Interestingly, teriparatide and zoledronate treatment were able to revert miRNA changes in tissue and serum of untreated OVX animals, such as the up-regulation of miR-203a-3p, a known osteo-inhibitory miRNA.
    2 context sentences
    Summary · context
    Eight weeks after surgery, OVX animals were further randomized to anti-resorptive treatment with zoledronate (n=11), osteo-anabolic treatment with teriparatide (n=11), or vehicle treatment (n=10).
    Summary · context
    After 12 weeks of treatment, bone and serum samples were used for microRNA analysis using next-generation sequencing (NGS), mRNA levels using RT-qPCR, and bone microarchitecture analysis using nanoCT.

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 04AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Mechanism

    In rat femoral head, miRNA changes during teriparatide and zoledronate treatment were associated with altered target activity including Dlx5.

    In plain wordsIn rats, miRNA changes during teriparatide and zoledronate treatment were linked to altered target activity including Dlx5.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Direction not reportedDlx5 target activity
    Study

    Sprague-Dawley ratsn: not reported in source

    Ovariectomized rats
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    These changes are associated with altered activity of target genes relevant to bone formation, such as Dlx5.
    3 context sentences
    Summary · context
    Our data reveal a significant effect of ovariectomy-induced bone loss, as well as the two major types of anti-osteoporotic treatment on miRNA transcription in femoral head tissue.
    Summary · context
    Eight weeks after surgery, OVX animals were further randomized to anti-resorptive treatment with zoledronate (n=11), osteo-anabolic treatment with teriparatide (n=11), or vehicle treatment (n=10).
    Summary · context
    After 12 weeks of treatment, bone and serum samples were used for microRNA analysis using next-generation sequencing (NGS), mRNA levels using RT-qPCR, and bone microarchitecture analysis using nanoCT.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.